• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Acorda Therapeutics wins FDA NDA nod for Inbrija

February 20, 2018 By Fink Densford

Acorda Therapeutics

Acorda Therapeutics (NSDQ:ACOR) said today that the FDA accepted the New Drug Application for its Inbrija investigational inhaled levodopa product designed for treating symptoms of OFF periods in patients with Parkinson’s disease who are taking carbidopa/levodopa regimens.

The approval comes with a target date of October 5, 2018, the Ardsley, N.Y.-based company said.

The NDA comes supported by data from the company’s Phase 3 safety and efficacy study and from two long-term safety studies of patients with Parkinson’s disease. Results from these studies were presented at the International Congress of Parkinson’s Disease and Movement Disorders last June.

“OFF periods greatly disrupt the lives of people living with Parkinson’s, and there is a significant need for new treatments in this community. We are excited about the potential to bring this highly innovative treatment option to people living with Parkinson’s, and look forward to working with the FDA throughout the review process,” Acorda chief medical officer Dr. Burkhard Blank said in a prepared statement.

The phase I and II studies of Inbrija were funded in part by grants from the Michael J. Fox Foundation for Parkinson’s Research, Acorda said.

“People with Parkinson’s and physicians need more options to manage this disease. Inhaled delivery of levodopa could help the many people living with Parkinson’s facing the complication of OFF periods as their disease progresses,” Michael J. Fox Foundation CEO Todd Sherer said in a press release.

Earlier this month, Acorda saw shares fall after the biotech company met sales expectations on Wall Street with its fourth-quarter results, but missed EPS estimates.

Filed Under: Featured, Food & Drug Administration (FDA), Neurological, Pharmaceuticals, Regulatory/Compliance, Respiratory Tagged With: Acorda Therapeutics

IN CASE YOU MISSED IT

  • Embecta stock soars on first full-quarter results after BD spinoff
  • Abbott will spend $450M to up FreeStyle Libre production in Ireland
  • Better Therapeutics Q2 beats Street as it prepares to submit diabetes therapy for FDA review
  • Study backs Fluidx embolic device for vessel filling
  • Senseonics stock is up as it sticks by revenue guidance

Primary Sidebar

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Drug Delivery Business News in a minute? We Deliver!
Drug Delivery Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Signup for the newsletter

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing & Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts
Add us on FacebookFollow us on TwitterConnect with us on LinkedIn

Copyright © 2022 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS